PD-L1 Did Not Predict Immunotherapy Benefit in CC ...Middle East

Medscape - News
PD-L1 Did Not Predict Immunotherapy Benefit in CC
A post hoc analysis of the BEATcc trial showed that atezolizumab plus chemotherapy and bevacizumab provided clinical benefit regardless of PD-L1 status. Medscape Medical News

Hence then, the article about pd l1 did not predict immunotherapy benefit in cc was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( PD-L1 Did Not Predict Immunotherapy Benefit in CC )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News